The selective regulation of these genes by CDK12 is also evident in cancers with loss-of-function CDK12 mutations, such as high-grade serous ovarian carcinoma and metastatic castration-resistant prostate cancer, where a BRCAness phenotype with genomic instability sensitizes cells to DNA cross-linking agents and poly (ADP-ribose) polymerase (PARP) inhibitors11–13. The gene discussed is CDK12; the disease is ovarian serous carcinoma.